MedTrace Logo

Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

NCT03019029 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-03-16

No results posted yet for this study

Summary

The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

Conditions

  • Amyloidosis

Interventions

OTHER

18-F Florbetapir PET/MR scan

18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner

Sponsors & Collaborators

Principal Investigators

  • Stephen M. Broski, M.D. · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2022-03-24
Completion
2022-03-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019029 on ClinicalTrials.gov